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Abstract
Introduction: Chronic cannabis use has been associated with impaired cognition and elevated psychological
symptoms, particularly psychotic-like experiences. While D9-tetrahydrocannabinol (THC) is thought to be primar-
ily responsible for these deleterious effects, cannabidiol (CBD) is purported to have antipsychotic properties and
to ameliorate cognitive, symptomatic, and brain harms in cannabis users. However, this has never been tested in
a prolonged administration trial in otherwise healthy cannabis users. Here, we report the first study of prolonged
CBD administration to a community sample of regular cannabis users in a pragmatic trial investigating potential
restorative effects of CBD on psychological symptoms and cognition.
Materials and Methods: Twenty frequent cannabis users (16 male, median age 25 years) underwent a 10-week
open-label trial of 200 mg of daily oral CBD treatment, while continuing to use cannabis as usual. The majority of
participants were daily cannabis users who had used cannabis for several years (median 5.5 years of regular use).
Participants underwent psychological and cognitive assessments at baseline (BL) and post-treatment (PT) and
were monitored weekly throughout the trial.
Results: CBD was well tolerated with no reported side effects; however, participants retrospectively reported re-
duced euphoria when smoking cannabis. No impairments to cognition were found, nor were there deleterious
effects on psychological function. Importantly, participants reported significantly fewer depressive and
psychotic-like symptoms at PT relative to BL, and exhibited improvements in attentional switching, verbal learn-
ing, and memory. Increased plasma CBD concentrations were associated with improvements in attentional con-
trol and beneficial changes in psychological symptoms. Greater benefits were observed in dependent than in
nondependent cannabis users.
Conclusions: Prolonged CBD treatment appears to have promising therapeutic effects for improving psycholog-
ical symptoms and cognition in regular cannabis users. Our findings require replication given the lack of a pla-
cebo control in this pragmatic trial, but suggest that CBD may be a useful adjunct treatment for cannabis
dependence.
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The global trend toward legalization of cannabis for me-
dicinal and recreational use highlights an urgent need for
scientific investigation of the potentially harmful and
beneficial effects of its constituent compounds, particu-
larly in light of ongoing concerns regarding cannabis
exposure effects on health.1,2 Prolonged frequent use of
cannabis, particularly of high potency, has been associ-
ated with deleterious effects on psychological function,
including increased risk of developing psychosis,3,4 im-
paired cognition,5,6 and alterations to brain structure7
and function.8,9 These adverse outcomes have been as-
sociated with the action of D9-tetrahydrocannabinol
(THC), the primary psychoactive constituent of canna-
bis, and partial agonist at central cannabinoid (CB1) re-
ceptor sites.10 In contrast, the second most abundant
constituent within cannabis, cannabidiol (CBD), is
thought to have a broad range of therapeutic proper-
ties, including amelioration of the adverse psychologi-
cal and cognitive effects of THC.11 Unlike THC, CBD is
a low-affinity CB1 and CB2 receptor ligand and nega-
tive allosteric modulator of CB1, which reduces the
binding of CB1 agonists, while augmenting endocanna-
binoid tone in an indirect manner.12,13
Therapeutic effects of CBD have been reported across
a range of study designs and in different populations. In
studies examining naturalistic exposure to CBD through
hair analysis in regular cannabis users, greater concen-
trations of CBD have been associated with better cogni-
tive performance, especially memory,14 fewer psychotic
symptoms,15,16 and increased gray matter in the hippo-
campus.17 We recently demonstrated that naturalistic
exposure to CBD in cannabis users is associated with
normal hippocampal volumes relative to users exposed
to THC, but not CBD.18 This suggests that CBD may
be neuroprotective, perhaps through its role in synaptic
plasticity and/or neurogenesis. Animal studies have also
shown CBD to reverse THC-induced spatial memory
deficits,19 conditioned place aversion,20 and decreased
social interaction (for a review, see Refs.12,21), and im-
portantly, to increase hippocampal cell survival and neu-
rogenesis.22 Administration of pure compounds to
humans showed that CBD produces opposite effects to
THC in the nature of regional brain activation23 and
acute exposure to CBD ameliorates cognitive and
psychotic-like symptoms induced by THC in cannabis
users.24 Despite promising evidence of the therapeutic
effects of CBD, no study to date has examined the poten-
tially restorative effects of prolonged CBD administra-
tion to cannabis users.
This study is the first investigation of potential thera-
peutic effects of prolonged daily administration of CBD
to regular cannabis users using a pragmatic open-label
design, wherein cannabis users maintained their natural-
istic use of cannabis. On the basis of reviewed literature,
we focused on symptoms of depression, trait anxiety, and
psychosis-proneness,4,25,26 and cognitive performance
within the domains of attention/executive function and
learning and memory, being the most sensitive to the del-
eterious effects of chronic cannabis use.5 We hypothesized
that prolonged administration of CBD would improve
psychological functioning and cognitive performance in
regular cannabis users. We had no a priori hypothesis
regarding the effects of prolonged CBD exposure on
ongoing patterns of cannabis use, since potentially
diminished effects of THC could either result in a




Twenty cannabis users, recruited by advertising, partic-
ipated in this *10-week pragmatic open-label clinical
trial. Inclusion criteria required participants to have
used cannabis at least monthly for 6 months (the ma-
jority vastly exceeded this criterion; Table 2). Following
a telephone screen and a subsequent face-to-face semi-
structured interview (as previously used in our stud-
ies27,28), participants were excluded for any lifetime
head injuries requiring hospitalization, neurological
conditions, current psychiatric medication, and cur-
rent psychiatric diagnoses (personal, or first-degree
relative for psychotic disorders) or alcohol dependence
assessed using the Mini-International Neuropsychiat-
ric Interview—MINI Plus.29 Participants were also ex-
cluded based on self-reported history of regular other
illicit drug use (>once/month for >6 months in the
past 3 years); occasional recreational use (<once/
month) was not an exclusion criterion. Participants
were not required to alter their usual patterns of canna-
bis use; however, they were requested to abstain from
other drug use throughout the trial (self-report corrob-
orated by weekly urine drug screen) and from cannabis
and alcohol for at least 12 h before baseline (BL) and
post-treatment (PT) test sessions. Participants were
familiarized with study procedures before providing
written informed consent at each testing session and
received incremental reimbursements for participation
(completion total of AU$650). The study was approved
by the University of Wollongong and Illawarra
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Shoalhaven Local Health District Health and Medical
Human Research Ethics Committee and registered as
a clinical trial (ISRCTN89498802).
Procedure
The trial was conducted over 12 weeks, comprising
2 days of BL assessments, 10 weeks (on average) of
daily CBD administration, face-to-face weekly moni-
toring, and provision of CBD capsules, and minimum
12-h washout of CBD, cannabis, and alcohol before
2 days of PT assessments. The 2-day sessions occurred
mostly consecutively (maximum 1 week apart; CBD
administration maintained for PT sessions) and con-
sisted of structured interview, and clinical, cognitive,
electroencephalogram (EEG), and magnetic resonance
imaging (MRI) assessments (EEG and MRI outcomes
will be reported elsewhere). Specifically, beyond tele-
phone screening, the BL assessment at the University
included the following: (1) consent signing; (2) our cus-
tomized semistructured interview27,28 to further assess
demographic information, detailed history of current
and previous cannabis and other licit and illicit sub-
stance use, and cannabis-specific measures of withdrawal
(Cannabis Withdrawal Scale; CWS),30 dependence
(Severity of Dependence Scale; SDS),31–33 and (retrospec-
tively) experiences while intoxicated (Cannabis Experi-
ences Questionnaire; CEQ)34,35; (3) the MINI Plus to
screen for psychiatric disorders, and a range of scales
to assess symptoms of depression, anxiety, mood, and
psychosis liability, and global functioning (as primary
outcome measures—see section, ‘‘Psychological symp-
tom, cognitive and substance-related measures’’); (4)
the vocabulary and matrix subscales of the Wechsler
Abbreviated Scale of Intelligence36 to estimate full scale
IQ; and (5) height and weight were measured, and a
blood sample and urine sample were obtained (see sec-
tion ‘‘CBD administration and weekly monitoring’’). Par-
ticipants then proceeded to cognitive testing and the
EEG session, with an MRI session on the second day.
PT assessments were near identical, excluding only
those assessments required to be taken once (e.g., de-
tailed history and height). Follow-up telephone assess-
ments occurred 1 week, 1 month, and 3 months after
completion of the trial to monitor any withdrawal symp-
toms experienced as a result of ceasing CBD treatment,
general physical and mental well-being, and any changes
to substance use.
Psychological symptom, cognitive and substance-
related measures. The primary outcomes of this study
were psychological symptom and cognitive outcomes.
Table 1 provides a full listing of study measures and
their schedule of administration. To assess changes in
psychological symptoms following CBD treatment, par-
ticipants completed self-administered questionnaires re-
lated to depressive (Beck Depression Inventory; BDI37),
anxiety (State-Trait Anxiety Inventory38; STAI-I state
and STAI-II trait), and psychotic-like (Community
Assessment of Psychic Experiences; CAPE39) symp-
toms at BL and PT, and overall functioning (Global
Assessment of Functioning; GAF,40 and Social Occu-
pational Functioning Assessment Scale; SOFAS40) was
assessed by the researchers. Changes from BL to PT in
cognitive function were assessed using the Rey Audi-
tory Verbal Learning Test (RAVLT41; alternate
forms), and the Attention Switching Task (AST), a
task of executive function measuring cued attentional
set-shifting from the Cambridge Neuropsychological
Test Automated Battery (CANTAB Connect; iPad
Table 1. Baseline, Weekly, and Post-Treatment Measures
Measures Baseline Weekly sessions Post-treatment
Biological samples
Blood O O O
Urine O O O
Substance use related





Clinical symptoms and overall functioning
BDI O O O
STAI-I and STAI-II O O-I only O









The POMS, BPRS, and SPQ were administered for another study and
are not reported here.
AST, Attention Switching Task (CANTAB Connect; Cambridge Cogni-
tion); AUDIT, Alcohol Use Disorders Identification Test42; BDI, Beck
Depression Inventory37; BL, baseline; BPRS, Brief Psychiatric Rating
Scale50 (no changes were observed across weekly sessions); CAPE, Com-
munity Assessment of Psychic Experiences39; CEQ, Cannabis Experiences
Questionnaire34,35; CWS, Cannabis Withdrawal Scale30; GAF, Global
Assessment of Functioning DSM-IV-TR40; POMS, Profile of Mood States51;
PT, post-treatment; RAVLT, Rey Auditory Verbal Learning Test (adminis-
tered as per Lezak, 2004 with alternate forms at BL and PT)41; SDS,
Severity of Dependence Scale31–33; SOFAS, Social Occupational Function-
ing Assessment Scale DSM-IV-TR40; SPQ, Schizotypal Personality Ques-
tionnaire52; STAI-I and STAI-II: State-Trait Anxiety Inventory-I (state
anxiety) and -II (trait anxiety)38; TLFB, Timeline Follow-back procedure.43
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version). Changes from BL to PT were also assessed
for cannabis and alcohol-related cognitions and be-
haviors (CWS, SDS, CEQ, and the Alcohol Use Disorders
Identification Test; AUDIT42). Cumulative cannabis, al-
cohol, tobacco, and any other drug use were ascertained
weekly using the Timeline Follow-Back procedure
(TLFB).43 Participants were encouraged to report any ob-
served (positive or negative) effect of CBD treatment
through a semistructured interview.
CBD administration and weekly monitoring. At BL
and each weekly session, participants received 28
gelatin-coated capsules containing 50 mg of 99.5%
pure crystalline CBD (of herbal origin) solved in
Miglyol 812 and Softisan 378 (Trigal Pharma Ltd; a
subsidiary of the BioSynthesis Pharma Group Ltd).
Participants were instructed to swallow 4 (50 mg) cap-
sules per day (2 in the morning and 2 in the evening,
spaced to optimize steady-state plasma concentra-
tions), equating to 200 mg/day CBD. This dose was se-
lected as a ‘‘medium’’ level dose based on the range of
therapeutic doses reported in human studies (e.g.,
‡800 mg/day in psychotic individuals44,45), and for
caution since no previous study had administered pro-
longed and relatively high doses of CBD to ongoing
cannabis users. Participants received an SMS text mes-
sage (morning and evening) reminding them to take
their capsules. At each weekly session, participants
returned any unused capsules and were given a new
bottle containing 28 capsules for the following week.
Adherence was measured by the number of capsules
returned and participants reported the times of any
missed doses. Heart rate and blood pressure were mea-
sured; no significant variations occurred over the
course of the trial (data not reported). Blood samples
and urine samples (for drug screens and pregnancy
testing in females—an exclusion criterion) were taken
weekly. Plasma was analyzed by LC-MS/MS for canna-
binoid (CBD, THC, and THC metabolite) concentra-
tions.46 Urine samples were subjected to ProScreen
Dip Tests to corroborate self-reported abstinence
from drugs other than cannabis. All BL and PT urine
samples, and a random selection of samples provided
weekly during the trial proceeded to urinary drug
screen testing (total 98 urine samples analyzed; 5 sam-
ples per participant on average).
Statistical analyses
Statistical analyses were conducted using SPSS 24.0.
Primary outcome measures were change from BL to
PT in BDI, STAI-II, and CAPE (positive, negative,
and depressive psychotic-like symptoms) scores, in
performance on the RAVLT and AST, and in cannabis,
tobacco, and alcohol use measures. Significant change
was assessed by paired sample t-tests, or Wilcoxon
signed-rank tests for non-normally distributed data.
Outcomes were further explored by group: heavy ver-
sus light users according to median split on lifetime
occasions of use, and dependent versus nondependent
users according to cutoff scores on the SDS (‡3)47 at
BL, by repeated-measures ANOVA (rmANOVA) for
time by group interactions (with covariates as required),
or Wilcoxon signed-rank tests for skewed data. Spear-
man’s correlations explored associations between BL
and PT scores or change scores in psychological symp-
toms, cognitive performance, cannabis use measures,
CBD dose consumed (self-report), and plasma CBD
concentrations (mean, maximum, final week of trial,
and assessment day).
Results
Participant characteristics, patterns of cannabis use,
medication adherence, and plasma cannabinoid
concentrations
Demographic and substance use measures for the over-
all sample are provided in Table 2. Participants were
mostly young adult males (median age 25; 4 females)
and the majority had completed some tertiary educa-
tion. They were using cannabis on a median 25 days/
month and had been using regularly for a median of
5.5 years. The majority refrained from other illicit
drug use during the course of the trial, with one excep-
tion: one participant self-reported using LSD, ecstasy,
ketamine, mushrooms, or mescaline on multiple occa-
sions during the trial; none of these drugs were detected
in urinary drug screens and the self-reported use was
not alerted by the participant to the research team
until the trial was completed. Since this was a natural-
istic study of cannabis users in the community, and the
participant was not an outlier on any measure, his data
were retained in the analyses reported in this study.
Dependent users did not differ from nondependent
users in years of regular use or lifetime occasions of
use (although the latter was marginal at p = 0.054,
with 8 heavy and 4 light users in the dependent
group and 2 heavy and 6 light in the nondependent
group). Dependent and nondependent users also did
not differ in cumulative quantity of cannabis (cones),
alcohol (standard drinks), and tobacco (cigarettes) con-
sumed over the weeks of the trial (calculated from
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weekly TLFB interviews) (all p > 0.08). Only cumulative
cannabis use differed between heavy and light users, as
to be expected (median 1064 vs. 120 cones, p = 0.003; all
other p > 0.075).
The prolonged CBD treatment was well-tolerated
with no adverse effects during the trial or in the follow-
up period, including no withdrawal symptoms or
changes in cannabis or other drug use after ceasing
CBD treatment. Ten weeks of daily CBD treatment
was planned and completed by most participants, miss-
ing only occasional doses. However, in this pragmatic
community trial, a range of participant-related issues
(e.g., work commitments and scheduling difficulties
with PT appointments) resulted in one participant
completing only 5.5 weeks of CBD treatment, while
four participants continued to take CBD for 11–12
weeks to ensure PT sessions were conducted after a
similar washout period for all participants (‡12 h
after the last CBD capsule was consumed; median
15 h; range 12–23 h). Participants reported consuming
a median of 258 capsules over the course of the trial
(range 154–334), resulting in a total median dose of
12,900 mg CBD (range 7700–16,700 mg) over a median
10 weeks, with median adherence to consuming the
200 mg daily dose of 93.16% (range 68.67%–99.35%; me-
dian daily dose 200 mg; mean daily dose 184.05 mg, SD
13.99).
Average plasma CBD concentrations across the trial
are shown in Figure 1, demonstrating relative achieve-
ment of stable concentrations, although with much in-
dividual variability as expected for metabolism of this
compound following oral administration. No CBD
was detected in plasma at BL. Figure 1 also displays
concentrations of plasma THC and THC metabolites,
and Table 3 provides the weekly data across the trial
for each compound. Interestingly, average weekly
plasma CBD concentrations were positively correlated
with average weekly plasma THC-COOH concentra-
tions (r = 0.65, p = 0.017). Plasma CBD concentrations
were not significantly correlated with self-reported
dose of CBD consumed; Figure 1 nevertheless shows
a trend toward a relationship. Plasma CBD
Table 2. Participant Demographics and Cannabis, Tobacco, and Alcohol Use Measures at Baseline and Post-Treatment
Baseline Post-treatment t/Za p Effect size d/ra
n = 20
Age (years) 25.1 [20.6–46.8] —
Gender (M/F) 16/4 —
Education (years) 15.5 [11–23] —
IQ 113.4 (10.08) —
BMI 22.68 (2.86) —
Tobacco use (cigarettes/month)b 9 [0–540] 21.5 [0–308] 0.86 0.39 0.19
Alcohol frequency (days/month)b 4 [0–30] 8 [0–21] 1.53 0.13 0.34
Alcohol quantity (std drinks/month)b 19 [0–102] 29.8 [0–128] 1.14 0.26 0.25
AUDIT 8.70 (5.36) 7.60 (4.87) 2.05 0.47 0.55
Cannabis use
Age of first use (years) 17.34 (0.51) —
Age of onset regular use (years) 19.89 (0.47) —
Duration of regular use (years)c 5.17 [0.5–28.8] —
Duration of use lifetime 7.07 [4.2–31.8] —
Estimated lifetime occasions of use 1591 [141–8708] —
Past month frequency (days/30) 25.0 [2–30] 30.0 [3–30] 1.15 0.14 0.26
Past month quantity (cones)d 123.75 [9–1125] 105.0 [8–1080] 0.57 0.57 0.13
Cumulative quantity across the trial (cones)d — 381 [9.5–2195]
Time since last smoked (h) 17.17 [12–408] 17.25 [11.8–252] 1.92 0.055 0.43
CEQ
Euphoria 43.75 (9.54) 38.65 (8.53) 4.12 0.001 0.93
Paranoid/dysphoric 36.75 (7.24) 35.25 (5.62) 1.21 0.24 0.28
After effects 21.85 (8.60) 20.45 (6.72) 1.03 0.32 0.24
Amotivation 15.10 (6.06) 14.35 (5.32) 0.79 0.44 0.18
Psychotic 6 [4–13] 6 [4–11] 0.67 0.50 0.11
CWS 3 [0–29] 3 [0–32] 1.47 0.14 0.23
SDS 3.40 (2.37) 3.25 (2.17) 0.37 0.72 0.08
Mean (SD) or median [range].
aPaired samples t-test for normally distributed data; Wilcoxon signed-rank test for skewed data.
bFrom 30-day Timeline Follow-back.43
cDuration of regular use in regular users only.
dCones used in waterpipe; three cones are equivalent to one standard sized joint.
BMI, body mass index; SD, standard deviation.
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FIG. 1. Plasma concentrations of CBD (from administration; dashed line logarithmic fit to indicate likely
model without washout before PT), THC (from cannabis use external to the trial), THC-COOH and OH-THC
(metabolites of cannabis used externally) depicted across 10 weeks of CBD treatment, and after an at least 12-h
washout (PT) (solid line polynomial fit). Error bars indicate –1 SE. Average plasma CBD concentration across the
trial as a function of self-reported total dose (number of capsules) consumed by each individual (linear fit;
rho = 0.32, p = 0.17). CBD, cannabidiol; PT, post-treatment; THC, D9-tetrahydrocannabinol.
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concentrations did not differ between heavy and light
cannabis users, but dependent users had significantly
lower mean (10.11 ng/mL vs. 21.26 ng/mL; p = 0.006)
and maximum plasma concentrations (median 19.45
vs. 66.80 ng/mL; p = 0.002) than nondependent users,
despite not differing in self-reported total CBD dose
consumed ( p = 0.97). Subsequent analyses of symptoms
and cognition by group used rmANCOVA with mean
plasma CBD concentrations and cumulative cannabis
use measures from across the trial as covariates.
Cannabis frequency and quantity measures did not
change significantly from BL to PT (all p > 0.14). How-
ever, there was a significant decrease in CEQ euphoria
levels reported to be experienced after using cannabis
( p = 0.001 in the overall sample; no time by group
interactions, p = 0.005 after cumulative cannabis use in-
cluded as covariate), and many participants self-
reported feeling less high when they smoked cannabis
over the course of the trial. No other CEQ measures
were altered significantly from BL to PT, nor were mea-
sures of severity of dependence on cannabis (SDS) or
withdrawal from abstaining for at least 12 h before
each test session (CWS). There were no significant
changes in tobacco or alcohol use from BL to PT.
AUDIT scores marginally reduced overall ( p = 0.055)
and significantly in dependent users (BL 9.08 vs. PT
7.25) relative to nondependent users (BL 8.13 vs. PT
8.13) (time by group: p = 0.095; p = 0.043 with covari-
ates). SDS scores appeared to reduce in dependent
users (BL 5.01 vs. PT 4.50) and increase in nondepen-
dent users (BL 0.88 vs. PT 1.38), but the interaction was
not significant ( p = 0.20).
BL to PT differences in psychological symptoms
Table 4 reports psychological symptom measures at BL
and PT for the overall sample. Severity of depressive
symptoms (BDI) was significantly lower at PT than
at BL ( p = 0.017) (Fig. 2 depicts a linear decrease over
the weeks of the trial; r =0.78, p = 0.003). Participants
also reported significantly fewer positive psychotic-like
symptoms (CAPE-positive symptom frequency, p =
0.025) with lower levels of associated distress (CAPE-
positive symptom distress, p = 0.022) at PT. Reduction
in positive symptom frequency remained significant
after cumulative cones of cannabis smoked across the
trial was included as a covariate ( p = 0.014). There
were trends toward decreased overall symptom fre-
quency and distress (CAPE total frequency, p = 0.056;
total distress, p = 0.051). In contrast, state anxiety in-
creased PT relative to BL (STAI-I, p < 0.015). No
Table 3. Mean, Median, and Standard Deviation, and Minimum and Maximum Plasma Concentrations of CBD, THC,
THC-COOH, and OH-THC at Baseline, Across 10 Weeks of CBD Treatment, and After a ‡12-H Washout at Post-Treatment
BL w1 w2 w3 w4 w5 w6 w7 w8 w9 w10 PT
CBD (ng/mL)
Mean 0.1 5.8 10.4 10.7 18.4 19.4 19.7 23.6 11.6 19.4 26.0 7.8
Median 0.1 0.1 8.9 9.7 9.9 12.2 11.2 17.1 8.1 13.0 7.5 5.1
SD 0.1 8.6 8.7 5.3 18.3 19.8 20.9 17.4 8.1 21.1 41.6 7.4
Min 0.0 0.0 0.2 1.9 2.6 3.0 1.4 6.6 3.4 1.5 3.2 1.2
Max 0.3 27.9 36.6 21.4 65.8 59.8 76.5 65.3 32.7 70.8 129.5 31.0
THC (ng/mL)
Mean 5.9 5.4 8.7 6.0 6.7 9.2 10.0 8.9 9.9 10.3 8.4 7.4
Median 1.9 1.4 3.6 2.0 2.5 4.5 2.4 1.7 3.6 2.3 6.2 2.7
SD 9.8 7.2 14.6 7.9 8.1 15.3 15.0 14.9 15.2 16.2 9.3 8.5
Min 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Max 37.2 21.4 62.3 26.2 26.2 63.3 56.9 46.2 58.0 56.8 30.5 26.5
OH-THC (ng/mL)
Mean 2.0 2.7 2.4 2.7 3.1 3.3 4.3 3.1 5.3 4.0 4.5 3.2
Median 0.9 1.0 1.5 0.9 1.4 1.7 1.3 1.2 1.6 1.6 2.2 1.3
SD 3.3 3.5 2.7 4.1 3.5 4.9 6.0 4.4 8.6 5.2 6.0 3.9
Min 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Max 13.4 11.8 8.8 17.5 10.1 16.9 17.5 15.7 27.8 15.1 18.0 12.4
COOH-THC (ng/mL)
Mean 44.7 48.8 46.7 52.8 54.2 52.5 69.5 61.0 80.2 76.1 95.5 67.4
Median 18.9 28.7 27.2 23.4 30.8 32.7 28.8 21.2 27.6 26.6 61.6 25.3
SD 75.5 63.2 50.5 82.1 61.5 56.2 96.2 80.9 113.2 85.3 107.1 77.7
Min 0.2 0.5 0.6 0.2 0.2 0.2 0.1 0.5 0.3 0.5 0.1 0.2
Max 315.5 199.1 155.0 352.8 196.9 158.4 358.0 227.4 454.8 203.1 289.7 251.4
BL, baseline; CBD, cannabidiol; Max, maximum; Min, minimum; PT, post-treatment; THC, D9-tetrahydrocannabinol; w1–w10, week 1–week 10.
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changes were observed for trait anxiety, global or social,
and occupational functioning (Table 4). These results
suggest that prolonged CBD treatment may improve
depressive and positive psychotic-like symptoms in
regular cannabis users.
No significant time by group interactions were ob-
served on any measure when comparing groups of
heavy and light users with or without cumulative
cones smoked across the trial as a covariate. However,
in nonparametric tests for non-normal variables, only
heavy users showed a significant reduction in depres-
sive symptoms (median BL 3.0 vs. PT 0.0; Z = 2.53,
p = 0.011), while light users showed significant reduc-
tion in CAPE-positive symptom distress (BL 8.5 vs.
PT 2.5, Z = 2.05, p = 0.041).
Dependence status was far more sensitive to the ef-
fects of CBD treatment; significant time-by-group in-
teractions were observed for CAPE total frequency
( p = 0.018; p = 0.044 with covariates) and distress
scores ( p = 0.016; p = 0.026 with covariates), and
CAPE-negative frequency ( p = 0.002; p = 0.004 with
covariates) and distress scores ( p = 0.002; p = 0.007 with
covariates), with dependent users showing greater reduc-
tion in symptoms than nondependent users (Fig. 3).
CAPE-depressive symptom frequency scores showed a
significant reduction from BL to PT ( p = 0.025), which
did not interact with group. Dependent users showed sig-
nificant reduction in BDI scores (median BL 4.0 vs. PT
1.0; Z = 2.82, p = 0.005) and CAPE-positive symptom dis-
tress (BL 5.5 vs. PT 3.0; Z = 2.11, p = 0.035), with no
change observed in nondependent users. Furthermore,
only dependent users showed an increase in state anxiety
at PT relative to BL (median BL 23.5 vs. PT 30.5;
Z =2.19, p = 0.028). As shown in Table 5, at BL, depen-
dent users had significantly higher scores than nonde-
pendent users on the BDI and on CAPE total and
CAPE-negative symptom frequency scores, and sig-
nificantly lower GAF and SOFAS scores. At PT,
dependent users differed significantly only on the
GAF. These data support the evidence in Figure 3 of
greater potential efficacy of CBD treatment in depen-
dent users (who may have had more room to move)
than in nondependent users, closing the gap between
these groups.
BL to PT differences in cognitive performance
Verbal learning and memory performance as measured
by the RAVLT were superior at PT relative to BL, with
participants recalling more words across the five learn-
ing trials and postinterference, but not for delayed
Table 4. Psychological Functioning and Symptom Scores and Cognitive Performance at Baseline and Post-Treatment
Baseline Post-treatment t/Za p Effect size d/ra
BDI 2.5 [0–14] 0.5 [0–12] 2.49 0.013 0.39
STAI-I 23.5 [20–38] 29.5 [20–49] 2.43 0.015 0.38
STAI-II 32 [20–63] 32 [20–49] 1.19 0.23 0.19
GAF 85 [70–95] 85 [60–95] 0.88 0.38 0.14
SOFAS 85 [65–95] 85 [55–95] 0.88 0.38 0.14
CAPE
Frequency total 59.25 (10.22) 56.00 (8.97) 2.21 0.040 0.50
Distress total 23.25 (16.49) 18.40 (12.50) 2.35 0.030 0.58
Negative frequency 22.95 (4.49) 21.6 (4.78) 1.62 0.12 0.36
Negative distress 11.80 (7.36) 9.95 (6.71) 1.71 0.10 0.39
Positive frequency 24.60 (4.49) 23.00 (3.68) 2.65 0.016 0.62
Positive distress 3 [0–20] 2 [0–15] 2.29 0.022 0.36
Depressive frequency 11.70 (2.39) 11.40 (1.96) 0.56 0.58 0.13
Depressive distress 5.80 (4.57) 4.95 (4.26) 0.96 0.35 0.22
RAVLT
Words recalled Trials 1–5 52.55 (11.07) 56.00 (9.70) 2.25 0.038 0.53
Recall postinterference 10.30 (3.29) 11.42 (2.95) 2.30 0.033 0.54
Delayed recall 10.55 (3.35) 10.89 (3.25) 0.84 0.41 0.19
AST
Overall latency correct 518.65 (62.68) 492.60 (36.81) 2.44 0.025 0.63
Latency congruent 493.68 (56.96) 474.00 (38.68) 2.07 0.053 0.50
Latency incongruent 552.28 (68.49) 513.40 (42.55) 3.53 0.002 0.90
Latency switching trials 600.63 (86.21) 549.30 (53.40) 2.97 0.008 0.71
Switching cost 152.20 (70.80) 115.38 (68.78) 2.38 0.028 0.53
Mean (SD) or median [range].
aPaired samples t-test for normally distributed data; Wilcoxon signed-rank test for skewed data.
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recall (Table 4 and Fig. 2). There were no significant
time-by-group interactions.
In the AST, while accuracy did not significantly im-
prove, overall median reaction times were faster at PT
than BL overall ( p = 0.025) and for incongruent trials
( p = 0.002), with a trend for congruent trials ( p = 0.053;
Table 4). The latency difference between congruent and
incongruent trials was significantly smaller at PT than
BL ( p = 0.009), indicating less variation in performance
between trial types at PT due to faster responses in incon-
gruent trials. Importantly, performance improved signif-
icantly at PT in trials in which participants were required
to switch their attention between response rules, with
faster responding at PT ( p = 0.008; Fig. 2)—this variable
FIG. 2. Psychological symptom scores and cognitive performance in the whole sample across the CBD
treatment trial or at BL and PT: depressive symptoms (BDI scores) over the course of the trial; CAPE
positive, negative, and depressive symptom frequency (solid) and distress (dashed) scores at BL and PT;
RAVLT learning curves and total words recalled across trials 1–5 at BL and PT; CANTAB Attention Switching
Task switching cost as a function of plasma CBD concentration on the day of testing (rho =0.61, p = 0.006),
and latency during switching blocks at BL and PT. BDI, Beck Depression Inventory; BL, baseline; CAPE,
Community Assessment of Psychic Experiences; RAVLT, Rey Auditory Verbal Learning Test.
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FIG. 3. Psychological symptom changes from baseline to PT in dependent and nondependent cannabis
users. Group-by-time interactions for BDI scores (F1,18 = 8.29, p = 0.010); Alcohol Use Disorders Identification
Test scores (F1,18 = 3.10, p = 0.095); CAPE Total Symptom Frequency score (F1,18 = 6.82, p = 0.018); CAPE Total
Symptom Distress scores (F1,18 = 7.03, p = 0.016); CAPE-negative symptom frequency scores (F1,18 = 12.64,
p = 0.002); CAPE-negative symptom distress scores (F1,18 = 12.83, p = 0.002), and CAPE-positive symptom
frequency scores (F1,18 = 0.21, p = 0.649). Wilcoxon signed-rank Test for CAPE-positive symptom distress scores:
dependent users Z = 2.11, p = 0.035; nondependent users Z = 0.92, p = 0.356.
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being the key outcome measure from the AST (Cam-
bridge Cognition Ltd, 2017). Switching cost (the latency
difference between switching and nonswitching blocks)
was lower at PT than BL ( p = 0.028). There were no
time-by-group interactions for any AST variables. Pre-
vious research has demonstrated a practice effect on the
AST for switch errors and incongruent errors.48 No sig-
nificant change was observed on these variables from
BL to PT (both p > 0.34), arguing against a practice effect
in this study, and indeed negative correlations were ob-
served with plasma CBD concentrations, indicating
fewer errors PT with higher plasma CBD (rho range
0.40 to0.58, p range 0.08 to 0.007).
Association between plasma CBD concentrations,
patterns of cannabis use, and changes in
psychological symptoms and cognitive performance
Changes in cannabis use patterns, BDI scores, and
RAVLT performance were not associated with plasma
CBD concentrations. Changes in CAPE total dis-
tress (rho = 0.47, p = 0.037; Fig. 4), negative symptom
frequency (rho = 0.54, p = 0.015), and distress scores
(rho = 0.63, p = 0.003) were significantly correlated with
maximum plasma CBD concentrations. CEQ Psychotic
change scores correlated with total dose of CBD reported
to have been consumed (rho = 0.51, p = 0.022), but not
with plasma concentrations. Mean, maximum, or final
week plasma CBD concentrations were negatively corre-
lated with PT state anxiety and change in state anxiety
scores—the higher the average plasma concentration,
the greater the reduction in state anxiety (rho range
0.48 to0.62, p range 0.033 to 0.004) (even though PT
state anxiety levels were elevated relative to BL). This
implies that higher doses of CBD may alleviate anxiety,
but lower doses of CBD may potentially elevate state anx-
iety (Fig. 4), although this requires replication. No associ-
ations were observed for trait anxiety, which was the
primary focus of this study, as many confounding factors
could account for changes in state anxiety. Both BL and
PT severity of cannabis dependence (SDS) scores were
negatively correlated with mean, maximum, and final
week plasma CBD concentrations—the higher the plasma
CBD, the lower the SDS score (rho range0.43 to0.72,
p range 0.056 to 0.0003), with stronger associations at BL
than at PT (Fig. 4), but change in severity of dependence
was not correlated with plasma CBD concentration.
AST switching cost was significantly negatively cor-
related with plasma CBD concentrations on the day of
testing (rho =0.61, p = 0.006; Fig. 2) (indicating that
higher plasma CBD was associated with less variation
in latencies between switching and nonswitching trials;
i.e., less cost), as was response latency in switching
blocks (rho =0.45, p = 0.051; strengthening after re-
moval of one outlier: rho =0.50, p = 0.036), which
also correlated with mean (rho =0.55, p = 0.012)
and maximum (rho =0.53, p = 0.016) plasma CBD
concentrations. There was no evidence that better func-
tioning people may have taken more capsules, as there
were no associations between these AST measures at
BL and plasma concentrations attained in the trial.
There were no associations between AST measures
and hours since last CBD dose, indicating that im-
proved performance was not due to the acute effects
of CBD. In contrast, hours since last CBD dose did cor-
relate with postinterference (rho =0.53, p = 0.029)
and delayed recall (rho =0.55, p = 0.022) on the
RAVLT PT, and with change in delayed recall from
BL to PT (rho = 0.50, p = 0.041), suggesting that acute
effects of CBD may contribute to improved memory
function.
Table 5. Significant Symptomatic and Psychological Functioning Differences Between Dependent and Nondependent
Users at Baseline and Post-Treatment
Baseline Post-treatment
Dependent users Nondependent users p Dependent users Nondependent users p
BDI 4 [0–14] 0.5 [0–2] 0.004a 1 [0–9] 0 [0–12] 0.47
CAPE
Total freq 62.67 (10.95) 54.13 (6.73) 0.045a 56.67 (10.04) 55.00 (45–69) 0.69
Neg freq 24.50 (4.81) 20.62 (2.83) 0.036a 21.25 (5.29) 22.13 (4.19) 0.70
GAF 77.75 (7.71) 86.25 (6.41) 0.019a 79.08 (8.32) 87.50 (6.55) 0.027a
SOFAS 77.50 (8.92) 87.25 (4.20) 0.010a 79.67 (9.90) 87.75 (5.90) 0.053
Mean (SD) or median [range].
aSignificant between-group differences for dependent versus nondependent cannabis users at baseline and post-treatment.
CAPE Total Freq, CAPE total symptom frequency scores; CAPE Neg Freq; CAPE negative symptom frequency scores; Dependent, dependent cannabis-
user group (defined as ‡3 on the SDS at baseline); Nondependent, nondependent cannabis user group (defined at <3 on the SDS at baseline).




This is the first study to report the effects of a pro-
longed course of daily administration of CBD to canna-
bis users in the community. Ten weeks of 200 mg oral
CBD daily was well tolerated, with no side effects dur-
ing or after completion. In this pragmatic trial, the can-
nabis users were not seeking treatment and continued
their regular pattern of cannabis use during the trial
without restriction. Of note, significant reductions
in depressive and psychotic-like symptoms were ob-
served, along with improvements in cognition, from
BL to the end of treatment.
Caution must be observed in interpreting the results of
this open-label trial, as it was not placebo controlled and
given the exploratory nature of our analysis. As such, the
outcomes may be confounded by a range of bias, expec-
tancy, and practice effects. Nevertheless, the findings sug-
gest that CBD treatment may confer benefits to mental
health and cognitive function that are likely CBD treat-
ment specific, as correlations were observed with plasma
CBD concentrations. Furthermore, these beneficial out-
comes were observed in the context even of ongoing can-
nabis use. Within a treatment setting for cannabis users
seeking to reduce their cannabis use, adjunct use of CBD
alongside psychological treatments for cannabis depen-
dence may confer even greater benefits. This premise is
based on the following predicates: (1) the cannabis
users of this study reported experiencing less euphoria
when they smoked cannabis, both subjectively through-
out the trial and as measured by the CEQ. While
FIG. 4. Associations between plasma CBD concentrations, symptoms, and dependence.
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cannabis use in this study neither increased in compen-
sation, nor decreased, in a treatment-seeking sample mo-
tivated to reduce or stop using, provided with supportive
psychological treatment, the reduced euphoria may facil-
itate disincentive to continue using; (2) greater beneficial
effects of CBD were observed in dependent than nonde-
pendent users. This result speaks to the likelihood that
CBD confers greater therapeutic effects in a disease
state/compromised brain. For example, we recently
reported therapeutic neuroprotective effects of CBD
in a preclinical model of schizophrenia, where CBD
had no effect on cognition or social interaction (the neg-
ative symptoms of schizophrenia) in control animals.49
Similarly, in this study, cannabis users likely to have a
cannabis use disorder (based on SDS cut-off score ‡3)
showed significantly greater reduction in symptoms
and improved cognition than nondependent users. Inter-
estingly, both severity of dependence on cannabis and
AUDIT scores tended to decrease in dependent users
only. Dependent users also appeared to absorb or metab-
olize CBD differently to nondependent users, yet the
therapeutic effects of CBD held after controlling for
their lower mean plasma CBD concentrations. Further
research could look to optimizing CBD delivery and bio-
availability, using higher doses of CBD, and exploring
mechanistically these differential findings in dependent
versus nondependent cannabis users. We acknowledge
limitations regarding self-reported medication adherence
in terms of interpreting the altered metabolism apparent
in dependent users and we were unable to assay CBD
metabolites in this study; these would be informative in
future prolonged administration studies.
Together with our previous findings suggesting protec-
tion of brain harms by CBD,18 the current data provide
hope that even if cannabis users do not cease to use can-
nabis in the course of psychological interventions for can-
nabis dependence, adjunct treatment with CBD may
minimize any further harm from continued use. It may
be that the greatest efficacy would be achieved with
CBD treatment alongside abstinence from cannabis
use. Ascertaining the efficacy of CBD treatment in ab-
stinent, dependent users is an important avenue for fu-
ture research. There was little in the literature to guide
the dose of CBD employed in this protocol, and we
opted for a conservative/cautious dosing regimen for
this first-of-kind study. Further dose-finding studies
could manipulate not only the daily dose and its regi-
men (morning and evening dosing) but also the dura-
tion of treatment; we chose 10 weeks of treatment
for logistic and feasibility optimization purposes. This
was deemed long enough on the basis of other pharma-
cological clinical trials more generally, to show change
in symptoms and cognition, but not so long that signif-
icant attrition or nonadherence to trial inclusion crite-
ria might manifest (e.g., excess other drug use). Future
studies might also examine a range of other cognitive,
clinical and brain functional outcome measures.
Although our findings require replication in a larger
sample placebo-controlled trial, the potential for CBD
treatment to reduce psychological symptoms and
improve cognition in cannabis users, and be further de-
veloped as an adjunct to psychological treatments for
cannabis dependence, appears very promising.
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18. Yücel M, Lorenzetti V, Suo C, et al. Hippocampal harms, protection and
recovery following regular cannabis use. Transl Psychiatry. 2016;6:e710.
19. Fadda P, Robinson L, Fratta W, et al. Differential effects of THC- or CBD-
rich cannabis extracts on working memory in rats. Neuropharmacology.
2004;47:1170–1179.
20. Vann RE, Gamage TF, Warner JA, et al. Divergent effects of cannabidiol on
the discriminative stimulus and place conditioning effects of delta(9)-
tetrahydrocannabinol. Drug Alcohol Depend. 2008;94:191–198.
21. Malone DT, Jongejan D, Taylor DA. Cannabidiol reverses the reduction in
social interaction produced by low dose delta(9)-tetrahydrocannabinol
in rats. Pharmacol Biochem Behav. 2009;93:91–96.
22. Wolf SA, Bick-Sander A, Fabel K, et al. Cannabinoid receptor CB1 mediates
baseline and activity-induced survival of new neurons in adult hippo-
campal neurogenesis. J Cell Commun Signal. 2010;8:12.
23. Bhattacharyya S, Morrison PD, Fusar-Poli P, et al. Opposite effects of delta-
9-tetrahydrocannabinol and cannabidiol on human brain function and
psychopathology. Neuropsychopharmacology. 2010;35:764–774.
24. Englund A, Morrison PD, Nottage J, et al. Cannabidiol inhibits THC-elicited
paranoid symptoms and hippocampal-dependent memory impairment.
J Psychopharmacol. 2013;27:19–27.
25. Degenhardt L, Coffey C, Romaniuk H, et al. The persistence of the asso-
ciation between adolescent cannabis use and common mental disor-
ders into young adulthood. Addiction. 2013;108:124–133.
26. Lev-Ran S, Roerecke M, Le Foll B, et al. The association between canna-
bis use and depression: a systematic review and meta-analysis of longi-
tudinal studies. Psychol Med. 2014;44:797–810.
27. Solowij N, Jones KA, Rozman ME, et al. Verbal learning and memory in
adolescent cannabis users, alcohol users and non-users. Psychopharma-
cology (Berl). 2011;216:131–144.
28. Takagi M, Lubman DI, Walterfang M, et al. Corpus callosum size and shape
alterations in adolescent inhalant users. Addict Biol. 2013;18:851–854.
29. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International
Neuropsychiatric Interview (M.I.N.I.): the development and validation of
a structured diagnostic psychiatric interview for DSM-IV and ICD-10.
J Clin Psychiatry. 1998;59 Suppl 20:22–33.
30. Allsop DJ, Norberg MM, Copeland J, et al. The Cannabis Withdrawal Scale
development: patterns and predictors of cannabis withdrawal and dis-
tress. Drug Alcohol Depend. 2011;119:123–129.
31. Gossop M, Darke S, Griffiths P, et al. The severity of dependence scale (SDS):
psychometric properties of the SDS in English and Australian samples of
heroin, cocaine and amphetamine users. Addiction. 1995;90:607–614.
32. Martin G, Copeland J, Gates P, et al. The Severity of Dependence Scale
(SDS) in an adolescent population of cannabis users: reliability, validity
and diagnostic cut-off. Drug Alcohol Depend. 2006;83:90–93.
33. van der Pol P, Liebregts N, de Graaf R, et al. Reliability and validity of the
Severity of Dependence Scale for detecting cannabis dependence in
frequent cannabis users. Int J Methods Psychiatr Res. 2013;22:138–143.
34. Barkus EJ, Stirling J, Hopkins RS, et al. Cannabis-induced psychosis-like
experiences are associated with high schizotypy. Psychopathology. 2006;
39:175–178.
35. Barkus E, Lewis S. Schizotypy and psychosis-like experiences from recrea-
tional cannabis in a non-clinical sample. Psychol Med. 2008;38:1267–1276.
36. Wechsler D. Wechsler abbreviated scale of intelligence (WASI). Harcourt
Assessement: San Antonio, TX, 1999.
37. Beck AT, Ward C, Mendelson M. Beck depression inventory (BDI). Arch
Gen Psychiatry. 1961;4:561–571.
38. Spielberger CD, Gorsuch RL, Lushene R, et al. Manual for the State-Trait
Anxiety Inventory. Consulting Psychologists Press: Palo Alto, CA, 1983.
39. Stefanis N, Hanssen M, Smirnis N, et al. Evidence that three dimensions of
psychosis have a distribution in the general population. Psychol Med.
2002;32:347–358.
40. American Psychiatric Association (APA). Diagnostic and statistical manual
of mental Disorders (4th ed. text rev.). APA: Washington, DC, 2000.
41. Lezak MD, Howieson DB, Loring DW. Neuropsychological assessment. 4th
ed. Oxford University Press: Oxford, United Kingdom, 2004.
42. Saunders JB, Aasland OG, Babor TF, et al. Development of the alcohol
use disorders identification test (AUDIT): WHO collaborative project on
early detection of persons with harmful alcohol consumption—II.
Addiction. 1993;88:791–804.
43. Sobell LC, Sobell MB. Timeline follow-back: a technique for assessing
self-reported ethanol consumption. In Measuring alcohol consumption:
psychological and biological methods (Allen J, Litten RZ, eds.). Humana
Press: Totowa, NJ, 1992, pp. 41–72.
44. Leweke FM, Piomelli D, Pahlisch F, et al. Cannabidiol enhances ananda-
mide signaling and alleviates psychotic symptoms of schizophrenia.
Transl Psychiatry. 2012;2:e94.
45. McGuire P, Robson P, Cubala WJ, et al. Cannabidiol (CBD) as an adjunc-
tive therapy in schizophrenia: A multicentre randomized controlled
trial. Am J Psychiatry. 2018;175:225–231.
46. Galettis P. Development of a simple LCMSMS method for THC and me-
tabolites in plasma. Asia Pac J Clin Oncol. 2016;12:13–34.
47. Swift W, Copeland J, Hall W. Choosing a diagnostic cut-off for cannabis
dependence. Addiction. 1998;93:1681–1692.
48. Simen AA, Ma J, Svetnik V, et al. Efavirenz modulation of sleep spindles
and sleep spectral profile. J Sleep Res. 2015;24:66–73.
49. Osborne AL, Solowij N, Babic I, et al. Improved social interaction, recogni-
tion and working memory with cannabidiol treatment in a prenatal infec-
tion (poly I:C) rat model. Neuropsychopharmacology. 2017;42:1447–1457.
50. Overall JE, Gorham DR. The brief psychiatric rating scale. Psychol
Rep. 1962;10:799–812.
51. McNair DM, Lorr M, Droppleman LF. Manual for the profile of mood
states. educational and industrial testing services. Educational and
Industrial Testing Services: San Diego, CA, 1971.
52. Raine A. The SPQ: a scale for the assessment of schizotypal personality
based on DSM-III-R criteria. Schizophr Bull. 1991;17:555.
Cite this article as: Solowij N, Broyd SJ, Beale C, Prick J-A, Greenwood
L-m, van Hell H, Suo C, Galettis P, Pai N, Fu S, Croft RJ, Martin JH, and
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